Event-Driven Stocks

DBV Technologies S.A.

DBVTNasdaq

Healthcare · Biological Products, (No Diagnostic Substances) · I0 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 3 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$5.6M$4.2M$15.7M$4.8M$5.7M$11.3M
Operating income−$147.1M−$116.6M−$76.4M−$96.6M−$98.6M−$158.8M
Net income−$146.9M−$113.9M−$72.7M−$96.3M−$97.8M−$159.6M
Total assets$233.7M$65.7M$183.0M$246.5M$146.7M$272.2M
Total liabilities$64.9M$38.3M$42.8M$52.1M$47.4M$66.8M
Equity$168.8M$27.4M$140.2M$194.5M$99.3M$205.5M
EPS (diluted)$-1.05$-1.17$-0.76$-1.24$-1.78—
Shares out.136.9M102.8M96.4M94.1M54.9M54.9M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−2609.2%
Net margin
−2607.3%
Return on equity
−87.1%
Return on assets
−62.9%
Return on capital (ROCE)
−83.7%
Liabilities / assets
27.8%
Debt / equity
0.38×
Book value / share
$1.23
Revenue growth (YoY)
35.8%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-2.64distress
Accruals / assets
−11.0%clean
Piotroski F-Score
5/9mixed

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
62
/ 100
Profitability 0Growth 100Catalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 3 warning● 3 good
  • Altman Z″ in the distress zone
  • Filed a late-filing notice (Form NT) — missed an SEC deadline
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Revenue is growing year-over-year
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Risk flags

late SEC filings

A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
2 acquisitions6 disposalsnet −2.0M shares · last 8
InsiderDateTypeSharesPrice
Mohideen PharisOfficer — Chief Medical OfficerJan 29, 2026Sell534$4.86
Epic BpifranceDec 17, 2025Sell2.0M$4.84
Mohideen PharisOfficer — Chief Medical OfficerNov 20, 2025Sell6,496$2.88
Boucinha VirginieOfficer — Chief Financial OfficerNov 21, 2025Grant32,000$0.00
Trapp Kevin MichaelOfficer — Chief Commercial OfficerNov 21, 2025Grant55,000$0.00
Mohideen PharisOfficer — Chief Medical OfficerJul 29, 2025Sell464$2.22
Mohideen PharisOfficer — Chief Medical OfficerMay 22, 2025Sell397$1.84
Mohideen PharisOfficer — Chief Medical OfficerJan 30, 2025Sell600$0.85

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20261.8M10.1-0.8%
Apr 30, 20261.8M9.1+14.3%
Apr 15, 20261.6M6.4-6.0%
Mar 31, 20261.7M7.4+12.9%
Mar 13, 20261.5M4.5+12.8%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)